Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204 Silexion Therapeutics Corp. (NASDAQ: SLXN...
New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer Silexion Therapeutics Corp...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the...
RUNNEMEDE, N.J., Aug. 15 /PRNewswire-FirstCall/ -- Sielox, Inc. (OTC:SLXN) (BULLETIN BOARD: SLXN) , a developer, designer and distributor of security solution and industrial vision products...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0499 | 21.4993537268 | 0.2321 | 0.4658 | 0.207 | 40177588 | 0.33249975 | CS |
| 4 | -0.062 | -18.023255814 | 0.344 | 0.4658 | 0.207 | 10541661 | 0.33027598 | CS |
| 12 | -1.198 | -80.9459459459 | 1.48 | 1.7 | 0.207 | 6240803 | 0.49774155 | CS |
| 26 | -4.288 | -93.829321663 | 4.57 | 4.65 | 0.207 | 5632604 | 0.54772823 | CS |
| 52 | -4.288 | -93.829321663 | 4.57 | 4.65 | 0.207 | 5632604 | 0.54772823 | CS |
| 156 | -4.288 | -93.829321663 | 4.57 | 4.65 | 0.207 | 5632604 | 0.54772823 | CS |
| 260 | -4.288 | -93.829321663 | 4.57 | 4.65 | 0.207 | 5632604 | 0.54772823 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
